OR WAIT null SECS
February 15, 2024
There were no safety or efficacy issues identified in the FDA complete response letter for Lymphir, with no additional trials required.
Patients with severe frostbite who were administered Aurlumyn monotherapy experienced a significantly reduced risk of the need for amputation.
February 14, 2024
Augtyro was previously approved in November 2023 to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Onivyde (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) was found to improve overall survival in metastatic pancreatic adenocarcinoma.
February 13, 2024
Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.
BXCL701 combined with Keytruda (pembrolizumab) is being evaluated for patients with metastatic castration-resistant prostate cancer with small cell neuroendocrine and adenocarcinoma phenotypes.
February 12, 2024
In clinical trials, bepirovirsen was found to recognize the RNA used by hepatitis B virus to replicate in infected liver cells.
Eohilia, a corticosteroid developed specifically to treat eosinophilic esophagitis, is comprised of a novel formulation of budesonide taken twice daily for 12 weeks in patients 11 years of age and older.
February 09, 2024
Technavio analysis notes that an increase drug patent expirations could be a contributing factor.
February 08, 2024
The FDA placed a full clinical hold on magrolimab for hematologic cancers after data showed the drug in combination with azacitidine plus Venclexta increased the risk of death related to infections and respiratory failure in patients with acute myeloid leukemia.